Exozymes Inc.
EXOZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002010788
In the last 90 days, Exozymes Inc. insiders filed 1 open-market purchase and 0 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.05M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Exozymes Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 0 | 7 | +7 |
| Shares | 0 | 98.1K | +98.1K |
| Value | $0 | $1.62M | +$1.62M |
New holders (7)
Institutions that held Exozymes Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 50,460 | $832.6K | 0.00% |
| Citadel Advisors LLC | 27,652 | $456.3K | 0.00% |
| Geode Capital Management, LLC | 16,764 | $276.6K | 0.00% |
| BNP Paribas Arbitrage, SA | 2,113 | $34.9K | 0.00% |
| UBS Group AG | 707 | $11.7K | 0.00% |
| Tower Research Capital LLC (TRC) | 389 | $6.42K | 0.00% |
| Bank of America Corp | 15 | $248 | 0.00% |
Sold out (0)
Institutions that held Exozymes Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
None.